Rodman & Renshaw initiates coverage on Pharmacyclics (PCYC -0.1%) with a Market Perform...

|By:, SA News Editor

Rodman & Renshaw initiates coverage on Pharmacyclics (PCYC -0.1%) with a Market Perform rating and $20 price target. Analysts with the firm see more upside for the clinical-stage biopharmaceutical company even with a 149% YTD run up in shares on the books.